Statins may be next heart-failure drug

Cholesterol-lowering drugs called statins, which greatly reduce the risk of stroke and heart attack, may also help keep patients with heart failure alive even if they do not have high cholesterol, US researchers report.

Heart failure patients who took statins were 55 per cent less likely to die during the year after they were prescribed the drugs than patients who did not get them, a team at the University of California Los Angeles says.

"Our results were dramatic," Dr Gregg Fonarow, a professor of medicine who led the study, said yesterday.

"We were surprised by the magnitude of the additional benefits of statins in patients who were already on standard medications to treat heart failure."

Heart failure is a chronic but deadly condition caused by the heart's inability to pump efficiently. The heart gradually enlarges as it becomes weaker and weaker.

About 5 million Americans have the condition, which will kill half of them within five years. It can be caused by high blood pressure, valve disease, clogged arteries or even an infection.

Writing in the Journal of the American College of Cardiology, Dr Fonarow and colleagues said they found that heart-failure patients did better when given a statin drug no matter what the cause of their condition.

They analysed the records of 551 heart-failure patients and looked to see what medications each one was given. They then looked at mortality records.

They found an overall 55 per cent reduction in mortality rate for heart-failure patients taking a statin a year after getting the drug.

This finding held no matter whether they had high cholesterol.

It was also independent of age, sex, other drugs the patients were taking and other factors such as diabetes or coronary artery disease.

"If randomised clinical trials mirror our results, we may have a novel treatment for heart-failure patients," Dr Tamara Horwich said.

Statins may work by reducing inflammation, helping to better control the heart ventricles, or by decreasing an overactive sympathetic nervous system, Dr Fonarow said.

- REUTERS